Ophthalmology

Clinical trials for both AGTC-401 and AGTC-402 show promising results.

Short-term morphological rescue was seen after voretigene neparvovec-rzyl treatment.

Abeona Therapeutics is seeking a path towards BLA filing based on the promising clinical data.

NT-501 previously received orphan drug and fast track status from the FDA and Neurotech will pursue approval in late 2022.

Investigators found that reactivating the CaMKII enzyme could protect against further vision loss.

MCO-010 is designed to deliver multi-characteristic opsin to retinal cells.

Three patients continue to show improvements in BCVA 3 years post-treatment.

With advancements happening at unprecedented rates, these are the cell and gene therapy companies and pipelines we’re keeping a close eye on.

Investigators found that bilaterally treated participants experienced greater improvements in BCVA than unilaterally treated participants.

The OPTIC phase 1 study showed that the treatment was associated with a significant reduction in treatment burden after 1 injection.

The announcement follows positive results from the phase 1/2a trial of MCO-010 for RP.

Cynata Therapeutics' Ross Macdonald, PhD, discusses the company's pipeline and clinical-phase trials.

Investigators find approach improved vision and visual fields in some patients.

The chief scientific officer and chief medical officer at Eyevensys discuss the biotech company's pipeline and approach to gene therapy.

Detailed data from the phase 3 trial, including safety findings, which were in line with previous studies, will be presented at a future scientific meeting.

Details enhance knowledge of biological pathways that contribute to disease pathogenesis.

The chief medical officer of Eyevensys discussed the company’s work in developing sustained drug delivery systems.

RGX-314 may be a promising therapeutic option for exudative AMD.

An overview of new gene therapy options for wet AMD that are currently being explored in clinical trials.

Locanabio CEO James Burns, PhD, discusses the firm's targeted approach to treating genetic disorders of the central nervous system and the eye.

Nanoscope Therapeutics Inc. expects to advance the therapy by launching a late-stage Phase 2b trial this summer with gene therapy that delivers multi-characteristic opsin to retinal cells.

According to the company, preclinical study results from a 42-day proof-of-concept in vivo study demonstrated a single, intralacrimal gland injection of an adeno-associated virus containing the NGF gene produced statistically significant increase in NGF in tear film, as compared to placebo, as early as Day 7.

OpRegen led to restoration of retinal tissue for 75% of patients with dry AMD and geographic atrophy who received the treatment across a wide area of atrophy.

Ross Macdonald, PhD, managing director and CEO of Cynata Therapeutics, discusses the biotech company's approach to overcoming reproducibility challenges with mesenchymal stem cells.

Highlighting the latest ophthalmology-related news reported across MJH Life Sciences™.